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Abstract
Background: It is often the case that mammalian genes are alternatively spliced; the resulting alternate
transcripts often encode protein isoforms that differ in amino acid sequences. Changes among the protein
isoforms can alter the cellular properties of proteins. The effect can range from a subtle modulation to a
complete loss of function.
Results: (i) We examined human splice-mediated protein isoforms (as extracted from a manually curated
data set, and from a computationally predicted data set) for differences in the annotation for protein
signatures (Pfam domains and PRINTS fingerprints) and we characterized the differences & their effects on
protein functionalities. An important question addressed relates to the extent of protein isoforms that may
lack any known function in the cell. (ii) We present a database that reports differences in protein signatures
among human splice-mediated protein isoform sequences.
Conclusion: (i) Characterization: The work points to distinct sets of alternatively spliced genes with
varying degrees of annotation for the splice-mediated protein isoforms. Protein molecular functions seen
to be often affected are those that relate to: binding, catalytic, transcription regulation, structural molecule,
transporter, motor, and antioxidant; and the processes that are often affected are nucleic acid binding,
signal transduction, and protein-protein interactions. Signatures are often included/excluded and truncated
in length among protein isoforms; truncation is seen as the predominant type of change. Analysis points
to the following novel aspects: (a) Analysis using data from the manually curated Vega indicates that one
in 8.9 genes can lead to a protein isoform of no "known" function; and one in 18 expressed protein
isoforms can be such an "orphan" isoform; the corresponding numbers as seen with computationally
predicted ASD data set are: one in 4.9 genes and one in 9.8 isoforms. (b) When swapping of signatures
occurs, it is often between those of same functional classifications. (c) Pfam domains can occur in varying
lengths, and PRINTS fingerprints can occur with varying number of constituent motifs among isoforms –
since such a variation is seen in large number of genes, it could be a general mechanism to modulate
protein function. (ii) Data: The reported resource (at http://www.bioinformatica.crs4.org/tools/dbs/
splivap/) provides the community ability to access data on splice-mediated protein isoforms (with value-
added annotation such as association with diseases) through changes in protein signatures.
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Background
Human genome encodes a surprisingly low number of
genes; however a large transcriptome has been reported
for human [1-3]. Alternative splicing of exons, during the
processing of pre-mRNA, is a major contributor to the
diversity seen in transcriptome and proteome [4,5]. Tran-
script isoforms from a gene often encode functionally
diverse protein isoforms [5-9]. It has been reported that
gene regulation through alternative splicing is more versa-
tile than that through promoter activity [1,10]. The many
other mechanisms that the cell uses to introduce variation
at gene or transcript or protein level (such as RNA editing
and post-translational modifications) are themselves
affected by alternative splicing (for example, introduction
of protein domains that bring about post-translational
modifications [5]).
Alternative splicing leads to variants of proteins with
diverse changes that can range from profound effects to
fine modulation of protein activity [11]. An example that
illustrates drastic change can be seen among the isoforms
of caspase-9 protease: the constitutive form of the protein
induces apoptosis, while its shorter isoform acts as an
inhibitor [12]. An example that illustrates fine modula-
tion can be seen among the isoforms of AT1: the protein
product of human AT1 (angiotensin II type 1 receptor)
gene binds to angiogenesis II (Ang II) hormone peptide;
four transcript isoforms have been identified for hAT1
gene that essentially leads to two protein isoforms differ-
ing from one another by a 32-amino acid extension at the
N-terminal; the shorter isoform has higher affinity to the
hormone peptide than the longer isoform; the potency of
the Ang II response varies depending on the relative abun-
dance of these two protein isoforms [13].
Splice-mediated changes at transcript level can be seen in
both the untranslated and the coding regions. Changes in
the untranslated regions can lead to inclusion/exclusion/
modification of RNA regulatory elements responsible for
the translatability of the mRNA. Changes in coding
regions can lead to insertion/deletion/substitution of
amino acid residues in the encoded proteins and thereby
bring about differences in the constituent functional/
structural motifs; such changes in a protein can alter its
binding properties (e.g. in terms of the binding affinities
and the types of binding molecules), can influence its
intracellular localization (e.g. in terms of effecting changes
on signal peptides or localization signals), can modify its
enzymatic activity (e.g. in terms of effecting changes in
substrate specificity, catalytic properties or affinity), and
can modify its intrinsic stability (e.g. by introducing
regions for autophosphorylation or signals for cleavage)
[5,14]. The effects due to such changes can range from a
complete loss of function to very subtle activity modula-
tion. The 3-dimensional structure of a protein can be dras-
tically altered by splice-mediated deletion of large regions
or even of small regions that are part of long-range struc-
tural stabilizations; modeling studies [1,6] have reported
that up to 67% of alternative spliced isoforms can show
significant alterations in regions that form the core of pro-
tein structure and thereby large conformational differ-
ences. Tress et al [15] find little evidence as to whether a
majority of protein isoforms have a role as functional pro-
teins.
Missplicing events can cause or contribute to human dis-
eases. At least 15% of human disease-causing mutations
occur at splice sites [16]; mutations and genetic variations
can alter the splice site signals and splice regulatory ele-
ments to mediate formation of alternate transcripts and
protein isoforms [17-20]. Aberrantly spliced isoforms
play a direct role in transformation, motility and metasta-
sis of tumor tissue; array and RT-PCR experiments [21]
confirm that differentially expressed transcripts correlate
extremely well with known cancer genes and pathways;
and cancer-specific novel splice isoforms have been iden-
tified in human expressed sequence collections [22]. It is
important to characterize functional changes in protein
isoforms and to understand the association between the
pathological states of the cell and the synthesized protein
isoforms; this will help in developing novel peptide-based
probes and targets for identifying and treating human dis-
eases.
We considered two large data sets of splice-mediated pro-
tein isoform sequences from human and delineated dif-
ferences in signatures among the isoforms – the data sets
of examined protein isoforms are of two different types,
namely one from a database of manually curated isoforms
and the other from computationally predicted splice iso-
forms as seen in EST resources. Changes among protein
isoform sequences are discussed in terms of inclusion/
exclusion/alternation/truncation of protein signatures
(domains as defined by Pfam [23] and fingerprints (as
defined by PRINTS [24]) as well as in terms of lack of
annotation for signatures. We present to the community
the resultant database (SpliVaP) containing information
on changes in the composition and structure of signatures
among protein isoform sequences (with value-added
annotations such as associations with diseases).
Methods
Data on protein isoform sequences
For data on protein isoform sequences, we considered two
independent sources – one based on manually curated
database of splice isoforms, and another based on compu-
tational delineation of splice isoforms from EST
sequences.BMC Genomics 2008, 9:453 http://www.biomedcentral.com/1471-2164/9/453
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Manually curated data set
For curated data on splice-mediated protein isoforms, we
used Vega (The vertebrate genome annotation) database
[25] as available from http://vega.sanger.ac.uk/
Homo_sapiens/index.html. Vega acts as the central repos-
itory for the majority of genome sequencing centres to
deposit their annotation of human chromosomes. The
manual curation of the human genome in Vega is thus
performed by an international group of collaborators (see
http://vega.sanger.ac.uk/info/about/
man_annotation.html for details). We used release v31
(Apr 2008) of the Vega database for homo sapiens for the
current study. The data set was cleaned for redundant pro-
tein isoform sequences – if two or more protein isoform
sequences from a gene are identical to one another, only
one was retained. The such cleaned data set comprises
33502 protein isoforms from 9649 human genes.
Computationally predicted data set
We extracted data on splice-mediated protein isoforms
from Alternative Splicing Database (ASD) [26] as availa-
ble from http://www.ebi.ac.uk/asd. Release 3 [27] of the
ASD database for homo sapiens was used for the current
study; the data set was cleaned for redundant protein iso-
form sequences – if two or more protein isoform
sequences from a gene are identical to one another, only
one was retained. The such cleaned data set comprises
27,241 protein isoforms from 7,664 human genes. A brief
note on the derivation of data on protein isoform
sequences by the ASD pipeline is in order here. ASD pipe-
line uses EST/mRNA transcript sequence data to firstly
identify isoform splice patterns of a gene; nucleotide
sequence of an isoform splice pattern is derived by extract-
ing the appropriate exon regions from the gene sequence;
the relevant protein sequence corresponding to such a
splice pattern is then derived from the nucleotide
sequence of the splice pattern by adopting one of the fol-
lowing two approaches: (a) mRNA evidence: When one of
the transcript sequences confirming the splice pattern is
an mRNA with annotation for coding information (i.e.
start and end of translated region), the information is
used to translate the splice pattern sequence onto protein
sequence; such a derived protein sequence is annotated as
having mRNA experimental evidence; it is often the case
that such annotated mRNA entries are associated with
protein sequence entries in UniProt [28] database. (b)
ASD prediction: This is for those splice patterns that are
confirmed entirely by EST sequences or by mRNA with no
annotation for coding information. All regions starting
with ATG codon from the splice pattern sequence are
assessed for translatability; length of the translated pep-
tide and the overall match to a reference protein are
assessed. Thresholds based on ATG-context scores [29] (as
detected using a set of experimentally determined transla-
tion initiation codons on human mRNAs) are applied.
Longest open reading frame is then selected to give rise to
translated protein sequence.
Annotation of protein isoform sequences for PRINTS 
fingerprints and Pfam domains
Annotation for PRINTS fingerprints
A PRINTS fingerprint [24] is a group of conserved motifs
used to characterize a protein family. The fingerprint con-
cept is based on the fact that sequences of proteins from a
family hold in common subsequences (sequence motifs)
that usually relate to key functional elements or core struc-
tural elements; the motif is any conserved element seen in
the alignment of sequences forming a family. InterProS-
can [30] is a tool that identifies fingerprints in a given pro-
tein sequence. Annotation by InterProScan for a
fingerprint does not necessarily mean that all the constit-
uent motifs of the fingerprint are seen in a given protein
sequence. We aligned the protein isoform sequences from
our data sets with PRINTS fingerprint signatures using
InterProScan. We retained only those alignments with an
E-value ≤ 10-5. Annotation for fingerprints can produce
partial or total overlap in fingerprint definitions along the
length of the sequences; such isoforms numbered 2257 in
the case of Vega and 711 in the case of ASD.
Annotation for Pfam domains
Pfam is a large collection of multiple sequence alignments
and hidden Markov models covering many common pro-
tein domains and families. Alignments of the protein iso-
forms with Pfam definitions were performed by using
HmmPfam [31,32]. We retained only those annotations
with an E-value ≤ 10-5. Annotation of protein sequences
for Pfam domains can produce partial or total overlap in
domain definitions along the length of the sequences;
such isoforms numbered only 173 in Vega data set, and
405 in ASD data set.
Examining the protein isoforms for changes in signatures 
(fingerprints or domains)
For every gene, we firstly identified a reference protein
which is the longest of the expressed protein isoforms;
choosing the longest protein as reference is justified by an
observation that in only < 5% instances of genes, the long-
est peptide had fewer Pfam domains or PRINTS signatures
than the other isoforms. We then identified changes in
signatures as seen between such a reference protein and
each of the protein isoforms. Definitions of such splice-
mediated changes are illustrated in Figure 1. Splice-medi-
ated changes in an isoform is identified by firstly perform-
ing a dynamic alignment of the signature pattern of the
isoform with that of the reference protein. Three types of
alignments can result – (i) Same Patterns: the composi-
tion and order of the signatures are same in both the ref-
erence and isoform protein; however, this set of isoforms
can still contain truncation events (change in length of aBMC Genomics 2008, 9:453 http://www.biomedcentral.com/1471-2164/9/453
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Definitions of splice-mediated changes in the annotation for PRINTS fingerprints and Pfam domains among protein isoforms Figure 1










Definition of events with Pfam domains
A truncation event indicates that a 
domain 
undergoes change in length between 
two 
isoforms. 
A swap event indicates that a domain 
alternates with another between isoforms.
A reshuffle event indicates a change in the
positional order of  domains. 






Fingerprint A with 3 
constituent motifs.
Definition of events with PRINTS fingerprints
Insertion/deletion of fingerprints:
Class A: A 'complete' fingerprint seen 
with all constituent motifs in an 
isoform is not present in the other 
isoform.
Class C: A 'partial' fingerprint seen 
with only some of the constituent 
motifs is not present in the other 
isoform.
Truncation of fingerprints 
(Insertion/deletion of some of the 
constituent motifs of 
fingerprints):
Class B: A fingerprint seen in an 
isoform as 'complete' (with all its 
constituent motifs) is present in the 
other isoform as 'partial' with less 
motifs.
Class D: A fingerprint is seen in both 
the isoforms as 'partial' but in one 
isoform, the fingerprint is seen with 
more of the constituent motifs.
Swapping of fingerprints:
A fingerprint seen (as complete or 
partial) in an isoform is swapped with 
another in the other  isoform.
An insertion/deletion event indicates that a
domain seen in an isoform is not present 
in the other isoform. 
Fingerprint B with 2 
constituent motifs.BMC Genomics 2008, 9:453 http://www.biomedcentral.com/1471-2164/9/453
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Pfam domain or change in the number of constituent
motifs of a fingerprint at an aligned position). (ii) Totally
Different Patterns: none of the signatures seen in the ref-
erence protein is present in the isoform; and (iii) Patterns
with Changes: there are changes in the composition and
order of signatures between the reference and isoform
protein; however, at least one common signature could be
seen. The cases of Totally Different Patterns were not
taken up for further analysis because they can be results of
the artifacts in peptide delineations or results of strict cri-
teria used to annotate for signatures. The other two types
are taken up for further characterization as below: (i) The
Patterns with Changes are examined further for specific
types of changes (such as insertion/deletion, truncation,
swap, and reshuffle) by scrutinizing the aligned positions;
and (ii) the Same Patterns are examined further for trun-
cation event. In our alignment schema, a position is occu-
pied either by a signature or by a gap; the signature is
characterized by the name, number of constituent motifs
(in the case of fingerprints) or by the length in amino
acids residues (in the case of domains).
Insertion/Deletion and Truncation of PRINTS fingerprints
A PRINTS fingerprint is defined by a collection of constit-
uent motifs. A variety of changes in fingerprint patterns
can be seen among protein isoforms – none or only few
or all of the constituent motifs of a fingerprint predicted
in an isoform can be seen in the other isoforms. We cate-
gorized insertion/deletion changes seen between two iso-
form sequences onto 4 classes as defined below: Class A
event: A 'complete' fingerprint seen (with all its constitu-
ent motifs) in an isoform is totally lost in the other iso-
form; Class B event: A 'complete' fingerprint (with all its
constituent motifs) is seen in an isoform while some of its
constituent motifs are lost in the other isoform; Class C
event: A 'partial' fingerprint seen (with only some of the
constituent motifs) in an isoform is not seen in the other
isoform; Class D event: Both the isoforms possess the fin-
gerprint as 'partial', but one isoform shows more of the
constituent motifs. We term the Class A and C events as
Insertion/Deletion of fingerprints, and Class B and D
events as Truncation of fingerprints.
Insertion/deletion of Pfam domains
A gap in the aligned position leads to identification of
domain insertion/deletion. We observe in our data sets
that a considerable number of protein isoforms are anno-
tated with successive repeats of a domain. Such repeats
can be collectively considered as one entity of domain; in
instances of insertion/deletions of some of the repeats but
not all, we annotate the change as Insertion/Deletion –
Reduction of repeats; and when all the repeats are
involved, we annotate the change as Insertion/Deletion –
All repeats. We find that delineation of events is ambigu-
ous when a protein isoform is annotated with repeats of
domains, and we tend to ignore such instances for identi-
fying events.
Truncation of Pfam domains
Pfam domains are derived from alignments of a represent-
ative set of sequences. For each domain are available man-
ually verified multiple alignments, hidden Markov
Models (HMM) and full-alignments. A single protein can
belong to several Pfam families. For each database search,
sequences that score more than the family-specific thresh-
old are aligned to the HMM profile automatically to make
a full alignment. Thus domains can have more than one
defined region that can differ in length across taxonomy;
it is often the case that a domain can have a large defined
region of sequence on eukaryotic proteins as compared to
their homologs in prokaryotes. We examined the lengths
of every domain from aligned positions; and the domain
is considered to undergo truncation when the lengths dif-
fer by more than 5 amino acid residues at an aligned posi-
tion.
Swapping of signatures among protein isoforms
A swap event is indicated by two gaps at successive aligned
positions (one from each of the aligned reference and iso-
form protein sequence). A note on swap events with
PRINTS fingerprints: A fingerprint seen (either as 'com-
plete' or 'partial') in reference protein is swapped with
another fingerprint ('complete' or 'partial') in the isoform
sequence.
Reshuffling of signatures among protein isoforms
A reshuffle event is identified when the order of occur-
rence of 2 or more signatures as seen in the reference pro-
tein is reversed in the isoform sequence.
Quality check on the detection of events
The alignments of the signature patterns were manually
curated. Detected events from the alignments were dou-
ble-checked for correctness by developing scripts that
implement heuristics-based methods.
Associations of isoforms with structural data
In order to provide to community structural data corre-
sponding to protein isoforms, we performed BLAST [33]
alignments of the protein isoform sequences with the
sequences of structural entries in the Macromolecular
Structure Database (MSD) [34]. Structural data for a pro-
tein isoform sequence from our data set is considered to
be present in MSD, if the coverage ≥ 98.0% (i.e. at least
98% of the residues from the query sequence aligns with
the target sequence in MSD with no gaps) and the identity
is ≥ 98.0% (i.e. at least 98% of aligned positions are occu-
pied by same amino acid residue in both the query and
target sequences). For such isoform sequences, we made
associations with MSD entries in our database.BMC Genomics 2008, 9:453 http://www.biomedcentral.com/1471-2164/9/453
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Association with genetic disorders
Information on gene associations with diseases was
obtained from the resource of Online Mendelian Inherit-
ance in Man (OMIM) [35]. For each of the genes thus
associated, we extracted the PubMed Identifiers of the
journal articles cited in the OMIM entry. We then
extracted all the Mesh terms associated with these
PubMed Identifiers. These mesh terms and the OMIM
terms were attributed as keywords describing the associa-
tion of genes to diseases.
Examination of transcript isoforms (encoding the protein 
isoforms) for susceptibility to nonsense-mediated decay 
(NMD)
This was done for splice isoforms from the ASD data set.
Splice patterns corresponding to the protein isoforms
were extracted from the ASD database. If the position of
stop codon is seen mapped more than 50 nucleotides
upstream of the last exon-exon junction of the splice pat-
tern, then such a splice pattern is considered as a possible
target for nonsense-mediated decay [36-38].
Discussion
Varying degrees of annotation of protein isoforms for 
Pfam/PRINTS signatures
We considered two data sets (one from Vega and the other
from ASD) of human genes with at least two or more pro-
tein isoform sequences identified for each gene; the pro-
tein isoform sequences were then examined for the
presence of Pfam/PRINTS signatures. This exercise
resulted in four distinct data sets (See Figure 2 for flow of
data across different steps leading to the following distinct
data sets):
Set A (with Vega: 2106 genes; 0 annotated isoforms; 6668
unannotated isoforms from all the 2106 genes; with ASD:
3934 genes; 0 annotated isoforms; 12741 unannotated
isoforms from all the 3934 genes): This set contains those
genes for which none of the reported protein isoforms
could be annotated for Pfam/PRINTS signatures. The rea-
sons for lack of annotation may include (i) that the crite-
ria on thresholds used in the methodologies to review the
alignments of Pfam and fingerprints with the protein iso-
form sequences is strict; and (ii) that examining the
sequences only for Pfam domains and PRINTS finger-
prints is not enough and further resources may need to be
used.
Set B (with Vega: 1128 genes; 1128 annotated isoforms
from all the 1128 genes; 1826 unannotated isoforms from
all the 1128 genes; with ASD: 382 genes; 382 annotated
isoforms from all the 382 genes; 693 unannotated iso-
forms from all the 382 genes): This set contains those
genes for which only one of the protein isoform
sequences could be annotated and the other isoforms lack
annotation. It is possible to say that the only annotated
isoform represents the constitutively expressed protein
product and that any of its variants lack functions (within
the constraints highlighted above for Set A).
Set C (with Vega: 1742 genes; 4340 annotated isoforms
from all the 1742 genes; 1243 unannotated isoforms from
590 genes; with ASD: 670 genes; 1730 annotated isoforms
from all the 670 genes; 691 unannotated isoforms from
359 genes): This set contains those genes for which two or
more protein isoform sequences could be annotated but
no decipherable changes could be observed in the anno-
tation for signatures between the reference protein and
any of the isoforms. Though the annotated isoforms are
different from one another in amino acid sequence, they
do not exhibit any change in signatures – the possible rea-
sons are that (i) the amino acid differences are small and
do not affect the domain/fingerprint definitions; and (ii)
the regions that are different among the isoforms are not
annotated for domains/fingerprints and hence no change
in signatures is seen among the isoforms.
Set D (with Vega: 4673 genes; 15610 annotated isoforms
from all the 4673 genes; 2687 unannotated isoforms from
1385 genes; with ASD: 2678 genes; 8376 annotated iso-
forms from all the 2678 genes; 2628 unannotated iso-
forms from 1346 genes): This set contains those genes for
which two or more protein isoform sequences could be
annotated and changes in signatures could be seen
between the annotated reference and at least one of the
isoforms. Some of the isoforms of a subset of genes lack
annotation.
The observed varying degree of annotation indicate lack of
signatures in all or some of the protein products from cer-
tain genes; such a lack of annotation has been observed by
other researchers as well – e.g. based on the work using
full-length human cDNAs from H-invitational transcrip-
tome data, Takeda et al [39] find that in 20% instances of
alternatively spliced human genes, the protein products
lacked annotation for protein motifs. For the work under-
taken in this study (splice-mediated changes in protein
isoforms), Set D is the appropriate resource as it presents
a list of genes in which two or more protein isoforms
could be annotated for Pfam/PRINTS signatures and
changes in signatures could be deciphered among the pro-
tein isoforms. In all the subsequent discussions, the Set D
is used.
Splice-mediated events with PRINTS fingerprints among 
protein isoforms
Overlapping annotation for fingerprints and the effects that 
alternative splicing has
We found 610 peptides in Set D of the Vega data set to be
annotated in an overlapping manner, 513 of which haveBMC Genomics 2008, 9:453 http://www.biomedcentral.com/1471-2164/9/453
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Flow of data (on genes and protein isoforms) through methodological steps adopted to derive the Set D used for characteriza- tions Figure 2
Flow of data (on genes and protein isoforms) through methodological steps adopted to derive the Set D used 
for characterizations. The numbers given in red correspond to the ASD data set, and those given in print colour corre-
spond to the Vega data set. The number of genes in Set D forms 44.7% (33.4% in the case of ASD) of the genes from the start-
up data set, the number of (PRINTS and Pfam) annotated protein isoforms and unannotated protein isoforms form 41% and 7% 
(27.5% and 8.6% in the case of ASD), respectively of the isoforms from the start-up data set.
Remove redundant protein isoforms  
and retain genes with >= 2
protein isoforms
Remove redundant protein isoforms  
and retain genes with >= 2
protein isoforms
Genes/protein isoforms from Release v31 of Vega (& Release 3 
of ASD) database for  homo sapiens.  10453 genes with 38172
protein isoforms (8016 genes with 30491 protein isoforms) (>= 2 
isoforms per gene).
Genes/protein isoforms from Release v31 of Vega (& Release 3 
of ASD) database for  homo sapiens.  10453 genes with 38172
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the overlapping fingerprints from same top-level classifi-
cation (in ASD data set, the numbers are 552 and 472).
We raised a question as to how often alternative splicing
removes overlaps? We examined isoform pairs where one
or both the partners are from this set of peptides with
overlapping annotation. In 1548 instances of 2036 such
pairs from Vega data set, alternative splicing removed the
overlapping fingerprint(s) (in ASD data set, the numbers
are 788 of 1242) – this phenomenon can be considered as
an event by itself (though it can be treated as fingerprint
insertion/deletion).
Insertion/deletion, and truncation of fingerprints
Changes in fingerprints among the annotated protein iso-
forms were seen in a data set of 898 Vega and 774 ASD
genes. Classification of PRINTS events as insertions/dele-
tion of fingerprints (Classes A and C events), and trunca-
tion (Classes B & D events) (see the section on Methods)
is informative in terms of severity of the effects on the
function. Insertion/deletion events, where a fingerprint
(seen with all or some of the constituent motifs) is totally
lost between two isoform sequences, may bring severe
effects as compared to the other type (namely truncation,
where the fingerprint can still be seen in both the isoform
sequences  albeit  with differing number of constituent
motifs). Our data sets show that truncation of fingerprints
occurs in more number of genes than insertion/deletion
of fingerprints; truncation occurs in 848 Vega (in 734
ASD) genes while insertion/deletion occurs in 242 Vega
(in 226 ASD) genes. Since truncation events are seen in a
large number of genes, it could be that truncation of fin-
gerprints is a mechanism to modulate protein functional-
ities. It is to be mentioned here that the presented
fingerprint truncation phenomenon is different from the
N-terminal and C-terminal protein shortening (or trunca-
tion) that the splicing community talk about – it is usually
the case that in such protein shortenings, a signature is
completely lost. It is significant if the observed fingerprint
truncations are often seen not as part of the N- or C-termi-
nal shortenings but are seen in the internal regions of the
shorter isoforms. We examined how often the observed
truncations of fingerprints are results of N-, or C-terminal
protein shortenings as opposed to genuine internal trun-
cations. We define the fingerprint truncation as part of N-
or C-terminal protein shortening, if the number of amino
acid residues separating the truncated end of the finger-
print from the corresponding terminal of the shorter pro-
tein by less than 5 amino acids. The ratios of observed
truncations were seen as (part of N-terminal shortening :
genuine internal : part of C-terminal shortening = 1 : 7.6 :
1.5 in the case of ASD genes, and 1 : 8.8 : 1.9). Thus the
fingerprint truncations are not mainly due to alternative
start/stop codons. Table 1 lists the top-level classifications
of fingerprints that often undergo insertion/deletion and
truncation events in our data set; it is seen that the major
classes of fingerprints that undergo insertion/deletion/
truncation events are receptors, enzymes (hydrolases, oxi-
doreductases, and transferases), transport proteins, struc-
tural proteins, RNA- or DNA-associated proteins, and
'Domain' signatures (such as those of SH2/SH3, Ankyrin,
Apple and Kringle domains – see [40] for a list). The top-
ranking fingerprints from the above-mentioned classes
are signatures of: SH2 domain signature, C4-type steroid
receptor zinc finger signature, Steroid hormone receptor
signature, P450 superfamily signature, Neurotransmitter-
gated ion channel family signature, Secretin-like GPCR
family signature, Tyrosine kinase catalytic domain signa-
ture, and Short-chain dehydrogenase/reductase (SDR)
superfamily signature (See additional file 1: Additional
File 1 for a list of top 10 frequently observed fingerprints
that undergo insertion/deletion event among protein iso-
forms).
Swapping, and Reshuffle of fingerprints
In addition to the above-mentioned insertion/deletion
and truncation events, we looked for other events such as
swap (where a fingerprint seen, either as 'complete' or
'partial', in a protein sequence is swapped with another in
the isoform sequence), and reshuffle (where the posi-
tional ordering of fingerprints as seen in a protein
sequence is reversed in the isoform sequence). Just one
instance of swap was seen (in ASD data set; Vega data set
showed 4 instances but they are ambiguous because the
protein isoform is annotated with fingerprints that over-
lap in positions) and one instance of reshuffle (in Vega
data set – reshuffling among SH2DOMAIN and
SH3DOMAIN) event was observed.
Splice-mediated events with Pfam domains among protein 
isoforms
Relative frequencies of different splice events with domains
We observed splicing events associated with Pfam
domains in 4581 Vega and 2375 ASD genes. Truncation
in domain length is the most predominant event (at 54%
of the instances of Vega protein isoform pairs, at 35% of
the instances of ASD protein isoforms pairs) followed by
insertion/deletion of domains (at 46% of the instances of
Vega protein isoform pairs, at 29% of the instances of ASD
protein isoform pairs). Swapping of domains occurred in
few instances (56 Vega isoform pairs and 9 ASD isoform
pairs). Reshuffling of domains was observed in just one
pair of protein isoforms. Occurrence of truncation events
in a large number of instances can probably be associated
with regulation, while insertion/deletion events can be
associated with a regulation activity ranging from fine-
tuning to drastic changes (depending on the nature of the
domain and the context of the splicing event).BMC Genomics 2008, 9:453 http://www.biomedcentral.com/1471-2164/9/453
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Truncation of domains
Examination of protein isoform sequences for domains
that are expressed in different lengths revealed that the
data on domain truncations is more complex than we
expected; even when a region (corresponding to a
domain) is shortened by large extents, it is annotated by
HmmPfam for the same domain. Table 2 lists Pfam
domains that frequently undergo truncation (show differ-
ent lengths in protein isoforms) as ranked by the number
of genes encoding the domain in different lengths among
the protein isoforms. In each of the cases of listed
domains, a high percent fraction of the genes encoding
the domain exhibit domain truncation. In each case of
domains, a large number of variations in lengths is
observed; highest number of variations is seen in the cases
of Pkinase (52 variants), MFS_1 (33 variants), Serpin (30
variants), Trypin (23 variants) and Filament (23 variants)
domains. Examination of data on the extent of variation
in the lengths of regions, that could still be annotated for
same domains, reveals that the variation can be extensive
– e.g. a variation of more than 100 amino acid residues
could be seen in the cases of domains Pkinase, MHC_I,
Filament, PH, etc. Since a large number of domains (Vega:
1552 of 2057 distinct annotated domains; ASD: 1149 of
1592 distinct annotated domains) are seen to undergo
truncations in a large number of genes (Vega: 3532 of
4581 genes; ASD: 1779 of 2375 genes), it could mean that
truncation could be a mechanism to modulate the proc-
esses in which they are involved. As in the case of finger-
print truncations, we observe here that domain
truncations are not mainly due to N- or C-terminal short-
enings of the proteins; the ratios of observed domain trun-
cations are seen as (part of N-terminal shortening :
genuine internal : part of C-terminal shortening = 1.5 : 4 :
1). Thus the domain truncations are not mainly due to
alternative start/stop codons.
Insertion/Deletion of domains
We find that 933 of 2057 distinct annotated domains in
Vega (ASD: 673 of 1592 distinct annotated domains)
undergo insertion/deletion. Table 3 lists the top 20
domains that are often inserted or deleted among protein
Table 1: Classifications of fingerprints involved in insertion/deletion and truncation events.
Top-level PRINTS classifications of 
fingerprints
No. of observed events* affecting
the whole fingerprint& some of the constituent motifs of the fingerprint$
Type A – insertion/ 
deletion of a
'complete' fingerprint
Type C – insertion/ 
deletion of a
'partial' fingerprint
Type B – truncation  
of a 'complete' to
'partial' fingerprint
Type D – fingerprint is  
partial in both the
isoforms and possess differing
number of constituent motifs
Receptors 61 (23%) 23 (8%)1 5 9  (62%)1 3  (5%)
64 (22%) 33 (11%)1 5 3  (54%)3 3  (11%)
Enzymes: Hydrolases 11 (9%)4  ( 3%)9 0  (79%) 8(7%)
13 (10%)2  ( 1%)9 7  (73%)1 9   (14%)
Transport proteins:others 51 (27%) 15 (7%)1 0 0 (53%) 22 (11%)
27 (19%) 21 (15%)7 7 (55%) 15 (10%)
Enzymes: Oxidoreductases 17 (18%) 11 (11%)3 9  ( 41%)2 7  (28%)
11 (10%)1 9  (18%) 40 (38%)3 4  (32%)
Enzymes: Transferases 13 (14%)3  ( 3%)6 9  (78%)3  ( 3%)
17 (18%) 5 (5%)6 3  (68%)7  ( 7%)
Structural proteins 26 (15%)1 2  (7%)1 0 7  (62%)2 6  (15%)
13 (14%)6  ( 6%)4 9  (55%)2 0  (22%)
RNA- or DNA-associated proteins 17 (15%)3  ( 2%)6 7  ( 62%) 20 (18%)
17 (23%) 2 (2%)4 4  ( 60%)1 0   (13%)
PRINTS 'Domains' signatures 20(36%) 13 (23%) 21 (38%) 1(1%)
26(52%) 4 (8%)1 7  ( 34%)3   (6%)
Cytokines and growth factors 4 (14%)2  ( 7%)1 7  ( 62%)4  ( 14%)
6 (18%) 3 (9%)2 2  ( 66%)2  ( 6%)
Protein secretion and chaperones 0 (0%)2  ( 1 4 % ) 8  ( 57%) 4 (28%)
0 (0%)6  ( 2 6 % ) 1 1  ( 47%) 6 (26%)
*, Events of same insertion/deletion type involving fingerprint members of a PRINTS classification observed among multiple pairs of isoforms from a 
gene are counted as one. Per every type of insertion/deletion event, the observed numbers involving the five top scoring fingerprint PRINTS 
classification are underlined. In brackets are given values on what fraction of events involving the PRINTS classification is of the given insertion/
deletion type – values > = 35% are in bold; values < = 15% are in italics. Values for Vega data set are given in line 1 and values for ASD data set are 
given in line 2 in every row.
&, A fingerprint seen as either 'complete' (with all the constituent motifs) or 'partial' (with only some of the constituent motifs) in an isoform is 
deleted in the other isoform.
$, Some of the constituent motifs of a fingerprint ('complete' or 'partial') in an isoform are deleted in the other isoform.BMC Genomics 2008, 9:453 http://www.biomedcentral.com/1471-2164/9/453
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Table 2: Pfam domains that are frequently truncated among protein isoforms.
Domain No. of genes that encode the domain  
in different lengths among the protein
isoforms (& as percentage fraction of genes 
encoding the domain in the protein isoforms)$
Count of unique 
domain lengths @
Variation in lengths of 
the domain among isoforms
Minimal length Maximal length
Pkinase 116 (77%) 52 23 572
3 (8%) 5 199 486
C1-set 47 (43%)
Not seen in ASD 8 30 89
Ras 38 (92%)
Not seen in ASD 21 25 192
MHC_I 35 (70%) 7 36 178
3 (60%) 5 91 178
Trypsin 29 (60%) 23 32 261
20 (66%) 14 104 261
ABC_tran 29 (80%) 15 55 197
11 (68%) 9 80 199
Filament 26 (92%) 23 34 452
4 (100%) 6 142 400
PH 24 (25%) 15 26 241
6 (15%) 5 84 134
MFS_1 23 (92%) 33 82 537
6 (54%) 7 326 426
Serpin 22 (100%) 30 31 424
10 (100%) 13 140 378
P450 22 (100%) 22 86 463
13 (72%) 20 187 486
Proteasome 22 (100%) 11 29 191
9 (100%) 8 117 187
7tm_1 22 (70%) 24 25 459
16 (48) 17 149 388
Ion_trans 21 (63) 18 27 280
1 (10%) 2 208 220
RRM_1 20 (46%) 9 23 86
9 (34%) 4 46 72
DEAD 19 (67%) 17 27 188
9 (56%) 9 96 180
Pkinase_Tyr 19 (38%)
Not seen in ASD 17 50 301
Collagen 19 (37%)
Not seen in ASD 5 28 59
Tubulin 18 (100%) 13 46 227
2 (50%) 5 113 227
I-set 18 (37%)
Not seen in ASD 10 22 99
Helicase_C 18 (35%) 7 41 91
3 (12%) 3 55 76
Mito_carr 17 (73%) 14 26 146
13 (65%) 10 50 136
UQ_con 7 (87%) 8 28 144
12 (100%) 11 69 157
$, presents the number of genes that encode the domain as undergoing truncation event among the protein isoforms. In brackets, is given in terms 
of percentage fraction of genes that encode the domain in the protein isoforms. Values with Vega data set is shown in line 1, and values with ASD 
data set is shown in line 2.
@, the observed lengths were grouped in a manner that any two lengths that differ by 5 or less amino acids is considered as one unique length.BMC Genomics 2008, 9:453 http://www.biomedcentral.com/1471-2164/9/453
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Table 3: Top 20 Pfam domains that are often inserted or deleted among protein isoforms*.
Pfam Domain No. of genes$ Pfam Description of the 
domain
Associated GO terms Keywords associated with 
the domain
zf-C2H2 104 (75%) Zinc finger, C2H2 type Zinc ion binding Nucleic Acid binding
61 (48%)
PH 59 (62%) pleckstrin homology Intracellular signaling/
constituent of cytoskeleton
22 (44%)
Ank 54 (80%) Ankyrin repeat Protein-protein interaction
25 (34%)
ig 51 (82%) Immunoglobulin family Domains for cell surface 
recognition.
Not seen in asd
fn3 46 (77%) Fibronectin type III domain Multi-domain glycoproteins.
6 (28%)
SPRY 46 (77%) SPIa and the Ryanodine receptor
3 (75%)
Collagen 45 (88%) Collagen triple helix repeat Phosphate transport Extracellular structural proteins
8 (66%)
zf-C3HC4 44 (61%) Zinc finger, C3HC4 type 
(RING finger)
Protein binding, zinc ion binding Key role in ubiquitination 
pathway.
7 (50%)
Pkinase 44 (29%) Protein kinase domain ATP binding, protein kinase 
activity, protein amino acid 
phosphorylation
1 (2%)
PDZ 43 (66%) PDZ domain Protein binding Signaling
18 (42%)
KRAB 42 (46%) Kruppel-associated box present 
in proteins containg C2H2 
fingers.





C1-set 41 (37%) Immunoglobulin C1-set domain Cell-cell recognition, cell-
surface receptors, muscle 
structure, immune system.
1 (50%)
WD40 40 (83)% WD or beta-transducin repeats Signal transduction, 
transcription regulation, cell 
cycle control, apoptosis.
35 (38%)
EGF 40 (83%) Epidermal growth factor – like 
domain
Found in extracellular domain.
5 (18%)
SH3_1 40 (51%) Src homology 3 Signal transduction
4 (8%) related to cytoskeletal 
organisation.
Sushi 39 (97%) Complement control protein 




Helicase_C 32 (62%) Helicase conserved C-terminal 
domain
Nucleic acid binding Helicase
12 (44%)
I-set 32 (66%) Immunoglobulin I-set domain Cell-cell recognition, cell-
surface receptors, muscle 
structure, immune system
Not present in ASD
RRM_1 31 (72%) RNA recognition motif Nucleic Acid binding RNA binding
21 (46%)





LIM 19 (82%) LIM domain (Binding protein) Zinc ion binding Interface for protein-protein 
interactionBMC Genomics 2008, 9:453 http://www.biomedcentral.com/1471-2164/9/453
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isoforms. Examination of Gene Ontology (GO) terms
[41] and Pfam descriptions associated with these domains
reveals that the top three affected molecular processes are:
(i) regulation of transcription, as indicated by the appear-
ance of nucleic acid binding domains (such as zf-C2H2,
KRAB, WD40, RRM_1, and Helicase_C). (ii) signal trans-
duction as indicated by the appearance of domains such
as WD40, PDZ, PH, C2, CH, and SH3_1; and (iii) protein-
protein interaction as indicated by the appearance of
domains such as Ank, LRR_1, LIM, and KRAB. Apart from
these three major categories, we find cellular adhesion &
recognition (as indicated by the appearance of the Sushi,
ig, collagen, C1-set, EGF, I-set, and domains), and prote-
olysis as affected by domain insertion/deletion events.
These functional "categories" (nucleic acid binding, signal
transduction and protein-protein interaction) represent key
functions that include control of gene expression, inter-
cellular relationships or cellular signaling, and basic
molecular interactions of many biological processes. Pro-
tein isoforms affected by such insertion/deletion splicing
events probably act as molecular switches where a specific
function has to be quickly switched off – as substantiated
by literature reports that some spliced isoforms lacking an
exon (or a domain in our study) can have antagonist effect
(such as in the case of caspase-9 protease: the constitutive
form of the protein induces apoptosis, while its shorter
isoform acts as an inhibitor [42,43]).
Domain swapping
Variations in protein isoforms due to domain swapping
are less frequent as compared to domain insertion/dele-
tion and truncation events. We identified 65 instances of
protein isoform pairs (See additional file 2: Additional
File 2 for the list of these protein isoform pairs) wherein a
domain alternates with another. These 65 instances (3
from ASD data set and 62 from Vega data set) form a list
of 35 unique pairs of alternating domains (see Table 4).
Though the isoform sequences show repeats of domains
in 59 of these 65 instances of isoform pairs, it is fair to
believe that the domains patterns can be unambiguously
aligned to extract the swap events (we have marked these
instances in the database with a note as containing
repeats). Examination of the description of the alternating
domains (Table 4) reveals that a domain alternates often
with a domain of same structural or functional classifica-
tion; swapping between such similar domains probably
fine-tune the biological process – some of these exem-
plary pairs are: (Hormone_receptor, zf-C4; KRAB, zf-
C2H2; SCAN, zf-C2H2Ion_trans, Ion_trans_2; ig, I-set; I-
set, V-set, EGF_CA, EGF, etc).
Reshuffling of domains
No reshuffling event involving domains was observed in
our data sets.
Comparison among different events involving domains
Table 5 compares the gene and event distributions for dif-
ferent Pfam domains; the table illustrates a trend that cer-
tain domains show preference of an event over other types
of events. Some of the domains that particularly undergo
insertion/deletion events in a higher percent fraction of
genes (containing the specific domain) as compared to
truncation events are: zf-C2H2, PH, Ank, SPRY, KRAB,
WD40, Sushi and EGF. Domains that particularly undergo
truncation events in a higher percent fraction of genes
(containing the specific domain) as compared to inser-
tion/deletion events: Trypsin, Ras, MHC_1 and ABC_tran.
Use of both PRINTS and Pfam resources for annotating 
the protein isoforms
Examination of the genes and isoforms from Set D (that is
used for the analysis) indicate that PRINTS could annotate
898 Vega (774 ASD) genes with detectable changes in fin-
gerprints among isoforms, and Pfam could annotate 4583
Vega (2375 ASD) genes with detectable changes in
domains among isoforms. While only in the case of 9
Vega and 27 ASD genes none of the encoded protein iso-
forms could be annotated for Pfam domains, in the case
of 2729 Vega and 1466 ASD genes none of the encoded
protein isoforms could be annotated for PRINTS finger-
prints. As mentioned through in earlier sections, the
observations/interpretations (e.g. truncations being the
20 (74%)
Mito_carr 21 (91%) Mitochondrial carrier Transport, binding, membrane
19 (86%)
CH 16 (53%) Calponin homology domain Cytoskeletal/signal transduction
12 (66%)
Hormone_receptor 9 (32%) Ligand-binding domain of nuclear 
hormone receptor




Trypsin 20 (41%) Trypsin Proteolysis Proteolytic enzyme
11 (30%)
$, presents the number of genes in which the domain is seen as undergoing domain insertion/deletion event. In brackets, is given in terms of 
percentage fraction of genes containing the domain – in what percentage fraction of genes (that contain the domain), the domain undergoes 
insertion/deletion.
*, Line 1 gives values from Vega data set and line 2 gives values from ASD data set.
Table 3: Top 20 Pfam domains that are often inserted or deleted among protein isoforms*. (Continued)BMC Genomics 2008, 9:453 http://www.biomedcentral.com/1471-2164/9/453
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Table 4: Unique pairs of alternating Pfam domains
Domains participating in Swap Events (D1 <--> D2)
Domain D1 Domain D2 Description of Domain D1 Description of Domain D2
Hormone_receptor zf-C4 Ligand-binding domain of nuclear hormone 
receptor. Steroid hormone receptor activity; 
transcription factor activity. DNA-dependent 
regulation of transcription.
Zinc finger C4 type. Found in steroid/thyroid 
hormone receptors; transcription factor 
activity. Regulation of transcription.
KRAB Zf-C2H2 Kruppel-associated box. Nucleic Acid binding; 
DNA dependent regulation of transcription.
Zinc finger. Nucleic acid binding.
SCAN zf-C2H2 SCAN domain (named after SRE-ZBP, CTfin51, 
AW-1 and Number 18 cDNA). Found in several zf-
C2H2 proteins. DNA dependent regulation of 
transcription.
Zinc finger, C2H2 type. Zinc ion binding; 
nucleic acid binding.
Mito_carr efhand Mitochondrial carrier. Transport EF hand. Calcium ion binding. Signaling. 
Buffering/transport.
CH Plectin Calponin homology domain. Actin-binding family. 
Cytoskeletal/signal transduction
Plectin repeat. Found in Plakin proteins. Plasma 
and nuclear membrances.
sushi CUB Sushi domain (SCR repeat) Complement control 
protein (CCP) modules, or short consensus 
repeats (SCR). Complement and adhesion.
Structural motif in extracellular and plasma 
membrane-associated proteins.
RGS PDZ Regulator of G protein signaling domain. PDZ domain. Protein binding. Signaling
C2 PDZ Ca2+-dependent membrane-targeting module. 
Signal transduction/membrane trafficking
PDZ domain. Protein binding. Signaling
collagen emi Collagen triple helix repeat. Phosphate transport. 
Extracellular structural proteins
Found in extracellular proteins.
Nebulin LIM Nebulin repeat. Found in the thin filaments of 
striated vertebrate muscle. Actin-binding protein.
LIM domain (Binding protein). Zinc ion binding. 
Interface for protein-protein interaction
PH Pkinase_Tyr pleckstrin homology. Intracellular signaling/
constituent of cytoskeleton. Pkinase_tyr supposed 
to contain PH domains.
Protein tyrosine kinase. Mediates the response 
to external stimuli.
Tubulin-binding MAP2_projctn Tau and MAP protein. Tubulin-binding repeat. MAP domain (MHC class II analogue protein)
FHA BRCT Forkhead-associated domain. Phosphopeptide 
binding motif
BRCA1 C terminus domain. Phospho-protein 
binding protein.
NTP_transf_2 PAP_RNA-bind Nucleotidyltransferase domain. Poly(A) polymerase predicted RNA binding 
domain. Polynucleotide adenyltransferase 
activity.
Ion_trans Ion_trans_2 Ion transport protein Ion channel. Both are of same clan.
Orn_Arg_deC_N Orn_DAP_Arg_deC Pyridoxal-dependent decarboxylase, pyridoxal 
binding domain. Catalytic activity
Pyridoxal-dependent decarboxylase, C-terminal 
sheet domain. Catalytic activity.
MAM ig Adhesive function. Cellular component: 
membrance
Immunoglobulin domain
ig I-set Immunoglobulin Immunoglobulin intermediate. Both are of same 
clan.
I-set V-set Immunoglobulin I-set (intermediate) domain. I-set 
and V-set are of same clan.
Immunoglobulin V-set (variable) domain.
EGF_CA EGF Calcium binding EGF domain. EGF-like protein. Both are of same clan.
Hydrolase E1-E2_ATPase Haloacid dehalogenase-like hydrolase. Catalytic 
activity. Metabolic process
Hydrolase activity. ATP binding.
Radical_SAM Mob_synth_C Catalytic activity; iron-sulfur cluster binding. Molybdenum cofactor synthesis C. iron, sulfur 
cluster binding
Aconitase Aconitase_C Aconitase hydratase. Lyase activity. Aconitase hydratase. Hydro-lyase activity.
Filament Filament_head Intermediate filament protein. Structural molecule 
activity
Head region of intermediate filaments.
CNH Pkinase Citron and Citron kinase. Small GTPase regulator 
activity.
Protein kinase activity. ATP binding.
PSI Sema Plexin repeat. Membrane. Receptor activity Semaphorins. Secreted and transmembrane 
proteins.
GTP_EFTU_D2 GTP_EFTU Elongation factor GTP binding. Elongation factor
PARP WWE Poly(ADP-ribose) polymerase. Catalyses covalent 
attachment of ADP-ribose to DNA binding 
proteins
Mediates protein-protein interactions in 
ubiquitin and ADP ribose conjugation system.
Sushi An_peroxidase Complement control protein (CCP) modules, or 
short consensus repeats (SCR). Complement and 
adhesion
Animal haem peroxidase. Peroxidase activity.BMC Genomics 2008, 9:453 http://www.biomedcentral.com/1471-2164/9/453
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predominant event, and types of domains & molecular
processes being most affected) from the analysis of Pfam
or PRINTS have been supporting and complementing
each other.
Orphan protein isoforms?
Tress et al [15] find little evidence as to whether a majority
of protein isoforms, as identified in the ENCODE pilot
project [44], have a role as functional proteins; they find
substantial alterations in the 3-dimensional structures of
as high as 49 of the 85 protein isoforms. It has been
reported that there can be large conformational changes
among protein isoforms in 67% instances of alternatively
spliced genes [6]. Talavera et al [45] find that alternative
splicing affects protein sequence and structure in a more
drastic way as compared with other similar events (such as
gene duplication & divergence) that bring about diversity
in proteins. Takeda et al [39] find that in 20% instances of
alternatively spliced human genes, the protein products
lacked annotation for protein motifs. Further, it is known
that pipelines such as ASD use EST/mRNA sequences from
a variety of clones/CDNA libraries that are derived from
either healthy or diseased or even pooled tissues; and
curated data sets contain transcript/protein isoforms that
are expressed in diseased states of the cell; thus it is possi-
ble that some of the protein isoforms are indeed expressed
in diseased states and hence may lack any function.
We set out to identify such the set of protein isoforms that
we call as 'orphan' isoforms; this term refers to situations
where one or more (but not all) of the protein isoforms
from a gene lack any annotation for either Pfam domains
or PRINTS fingerprints. As mentioned earlier, examina-
tion of the protein isoforms led to four sets with varying
degrees of annotation for Pfam/PRINTS signatures; of
these, the Sets B-D may contain potential orphan iso-
forms. However, we consider only the Set D for the reason
that it includes only those genes for which two or more
isoforms could be annotated and decipherable changes in
signatures could be seen among the isoforms. Certain
details on the nature of observed orphan protein isoforms
are as discussed below:
(i) Length distributions of orphan isoforms
Set D for Vega data set contains a total of 18297 isoforms
of which 2687 isoforms lack any annotation for either fin-
gerprints or domains (the corresponding numbers for
ASD data set are 11004 and 2628). We examined length
distributions of protein isoforms and found that the aver-
age length of orphan isoforms is low at 128 amino acids
(109 in the case of ASD data set) while the average length
of annotated isoforms can be high at 449 amino acids
(360 in the case of ASD) and that of human proteins in
UniProt/SwissProt is 450 amino acids. The annotated iso-
forms peaked at around 125 amino acids; the distribution
for the orphan isoforms was seen to be distinct from that
of annotated isoforms, peaks earlier, and does not have
the pronounced tail. The observed low value for the aver-
age length of orphan isoforms is in the order of typical
lengths of single-domain proteins; domain lengths distri-
bution usually peak at around 100 residues [46].
(ii) Threshold criteria used to annotate for Pfam domains and 
PRINTS fingerprints?
We have used a threshold for E-value as ≤ 10-5for accept-
ing the annotation for Pfam domains and PRINTS finger-
prints (see the section on Methods). Relaxing the
requirement on E-value from 10-5 to 10-4, to 10-3, and to 1
reduces the count of orphan isoforms seen in Vega data set
by only 6%, 9% and 12%, respectively (in the case of ASD
data set, there is virtually no reduction). Thus it is possible
to say that the observation of orphan isoforms is not due
to threshold criteria used to annotate for domains and fin-
gerprints.
(iii) Quality of underlying splice patterns
The ASD pipeline uses transcript (EST/mRNA) sequences
to decipher splice patterns. We find that splice patterns of
at least 37% of orphan isoforms are supported by 2 or
more transcript sequences, and up to 44% are supported
by mRNA sequences; upon considering only those orphan
isoforms of length > = 125 amino acid residues (the
length at which the distribution of annotated protein iso-
forms was seen to peak), these values increase to 48% and
60%, respectively.
PH Oxysterol_BP pleckstrin homology. Intracellular signaling/
constituent of cytoskeleton
Oxysterol binding protein. Steroid metabolic 
process
Ank KH_1 Ankyrin repeat. Protein-protein interaction K homology domain. RNA binding
GON TSP_1 Proteinaceous extracellular matrix. Zinc ion 
binding. Metalloendopeptidase activitiy.
Thrombospondin type 1 domain. Cell adhesion
Thioredoxin DnaJ Participates in redox reactions. Heat shock protein binding
Collagen EMI Collagen triple helix repeat. Phosphate transport 
process. Connective tissue structures.
EMI domain. Participates in multimerization
HECT RCC1 HECT-domain (ubiquitin-transferase) Homologous 
to the E6-AP Carboxyl terminus. Ubiquitin-protein 
ligase; protein modification process.
Regulator of chromose condensation. Acts as a 
guanine-nucleotide dissociation simulator 
(GDS)
Table 4: Unique pairs of alternating Pfam domains (Continued)BMC Genomics 2008, 9:453 http://www.biomedcentral.com/1471-2164/9/453
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Table 5: Pfam domains and the undergoing events – Gene & events distribution$
Percent fraction of genes that show 
the following events with the domain.
Percent fraction of events as per 
the following types with the domain
Pfam domain No. of Genes that encode   
the domain (in how many of










Pkinase 149 (139) 29% 77% 27% 72%
48 (4) 2% 6% 25% 75%
zf-C2H2 138 (106) 75% 1% 98% 1%
127 (61) 48% 0% 100% 0%
C1-set 108 (86) 37% 43% 46% 53%
2 (1) 50% 0% 100% 0%
PH 94 (73) 62% 25% 71% 28%
50 (24) 44% 12% 78% 21%
Ank 67 (55) 80% 7% 91% 8%
72 (25) 34% 5% 86% 13%
ig 62 (52) 82% 8% 91% 8%
Not seen in ASD
fn3 59 (49) 77% 30% 71% 28%
21 (6) 28% 4% 85% 14%
SPRY 59 (48) 77% 5% 93% 6%
4 (3) 75% 0% 100% 0%
Trypsin 47 (47) 42% 68% 38% 61%
36 (29) 30% 55% 35% 64%
PDZ 65 (46) 66% 27% 70% 29%
42 (20) 42% 11% 78% 21%
zf-C3HC4 72 (46) 61% 4% 93% 6%
14 (7) 50% 0% 100% 0%
Collagen 51 (45) 88% 37% 70% 29%
12 (8) 66% 0% 100% 0%
KRAB 90 (43) 46% 2% 95% 4%
69 (34) 49% 1% 97% 2%
SH3_1 77 (43) 51% 9% 85% 14%
45 (4) 8% 0% 100% 0%
WD40 48 (43) 83% 18% 81% 18%
90 (35) 38% 2% 94% 5%
Sushi 40 (40) 97% 27% 78% 22%
23 (17) 73% 4% 94% 5%
EGF 48 (40) 83% 8% 90% 9%
27 (5) 18% 0% 100% 0%
Ras 41 (39) 4% 92% 5% 95%
Not present in ASD
Helicase_C 51 (38) 62% 35% 64% 36%
27 (13) 44% 11% 80% 20%
RRM_1 43 (38) 72% 46% 60% 39%
45 (24) 46% 20% 70% 30%
MHC_I 50 (35) 12% 70% 14% 85%
5 (3) 0% 60% 0% 100%
ABC_tran 36 (33) 50% 80% 38% 61%
18 (13) 38% 61% 38% 61%
zf-B_box 47 (33) 46% 25% 64% 35%
14 (3) 21% 0% 100% 0%
C2 44 (32) 61% 36% 62% 37%
30 (17) 53% 10% 84% 15%
LIM 23 (22) 82% 39% 67% 32%
27 (20) 74% 14% 83% 16%
Mito_carr 23 (22) 91% 73% 55% 44%
22 (19) 86% 59% 59% 40%
$, Line 1 gives the values from Vega data set and Line 2 gives the values from ASD data set.
Domains that particularly undergo insertion/deletion events in a higher fraction of genes (containing the specific domain) as compared to truncation 
events are: zf-C2H2, PH, Ank, SPRY, KRAB, WD40, Sushi, and EGF. Domains that undergo truncation events in higher fraction of genes (containing 
the specific domain) as compared to insertion/deletion events: Trypsin, Ras, MHC_1, and ABC_trans. Since Swap events were seen in few instances, 
they are not considered in deriving this tableBMC Genomics 2008, 9:453 http://www.biomedcentral.com/1471-2164/9/453
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(iv) Transcripts corresponding to orphan isoforms and nonsense-
mediated decay (NMD)
It is known that certain alternative splice events lead to
transcripts that are targeted for nonsense-mediated decay
[36-38]. Upon examination of the ASD splice patterns
corresponding to the orphan isoforms for susceptibility to
nonsense-mediated decay, it is seen that only in 5.5%
instances of orphan isoforms, the transcripts are putative
candidates for nonsense-mediated decay. This extent is
much lower than the reported estimates (namely that one
in five to one in three alternatively spliced transcripts are
susceptible to NMD [36-38]). Instances of transcripts sus-
ceptible to NMD can be seen even with annotated protein
isoforms – the corresponding values in the case of anno-
tated protein isoforms are 7.9% – suggesting that the
observed orphan isoforms are particularly not artifacts
due to lack in validating transcript data for NMD. It is
appropriate to recollect from literature that NMD machin-
ery rarely down regulates the expression of a transcript
completely; 10–30% of transcripts containing premature
stop codons survive (NMD-escape) and may lead to pro-
duction of physiologically relevant levels of truncated
protein products [47,48].
(v) The orphan protein isoforms probably lack any known function
The transcript sequences (confirming the isoform splice
patterns in the ASD pipeline) are derived from clone/
cDNA libraries with the tissue state as normal or disease
disorder or as pooled/mixed; e.g. upon querying the ASD
database for the count of genes with transcripts seen
expressed in normal versus neoplasia cDNA libraries, it is
seen that (i) for 10477 genes, at least one of the expressed
transcripts is from cDNA libraries with pathological state
as normal; and (ii) in roughly equal number of genes at
9590, at least one of the expressed transcripts is from
cDNA libraries with neoplasia as pathological state. Aber-
rantly expressed splice patterns are seen in diseased cells,
such as cancer [49]; the number of aberrant splicing proc-
esses causing human disease is growing exponentially (see
[50] for a review). Thus, it is quite possible that the
orphan protein isoforms are seen probably as results of
aberrant splicing in disease states of the cell and hence
they lack annotation for signatures. It is important to note
that the signatures seen in the constitutive protein (and in
some of the encoded isoforms) are totally lost in orphan
isoforms and hence the functions associated with the con-
stitutive protein are lost in the orphan isoforms. Further,
it is safe to say that Pfam and PRINTS are probably com-
prehensive enough to report signatures of 'known' func-
tions. Hence we can say that the orphan isoforms lack any
'known' function.
(vi) Estimates for orphan protein isoforms
A wild estimate is one that is based on unannotated pro-
tein isoforms of all lengths. Vega data set: Of 18297 iso-
forms (from 4673 genes), 2687 isoforms (from 1385
genes) are orphans; ASD data set: of 11004 isoforms
(from 2678 genes), 2628 isoforms (from 2628 genes) are
orphans. Such a wild estimate is: From Vega data set: (a)
one in every 3.4 genes can express an orphan protein that
lacks any "known" function, and (b) One in every 6.8
alternative splice events can result in transcript isoform
that encodes a protein lacking any "known" function;
From ASD data set: one in every 1.02 genes and one in
every 4.2 isoforms. A conservative estimate can be
obtained by ignoring short isoforms of length < 125 resi-
dues – in Vega data set, of 13591 isoforms (from 4248
genes) of lengths > = 125 amino acid residues, 722 iso-
forms (from 477 genes) are orphans. The conservative
estimate as seen in Vega data set is: one in 8.9 genes can
be seen to lead to a protein isoform of no "known" func-
tion; and one in 18 protein isoforms can be such an
orphan isoform; the corresponding numbers as seen in
ASD data set are: one in 4.9 genes and one in 9.8 isoforms.
We wish to emphasize that these estimates are subject to
corrections for regulations, such as NMD, RNA silencing
at transcript level and decay by cellular degradation
machinery at the protein level; however, we believe that
such corrections are probably taken care by the elimina-
tion of protein isoforms of shorter lengths in deriving the
conserved estimate.
Concerns & Caveats
Certain concerns, that may arise due to the methodologies
& the nature of the data resources are discussed below.
(i) Repeats
Annotation of a fair number of isoforms comprises
repeats of a single or multiple signatures. Delineating
events from such annotation is difficult and can lead to
ambiguous results. In such instances, we avoided delinea-
tion of events.
(ii) E-value thresholds
There can be instances where the E-values are close to the
chosen threshold but still not good enough to accept the
annotated domain/fingerprints and such instances can
lead to identification of further events.
(iii) Underlying splice events
One may raise a concern that the events of domain dele-
tion, swapping and reshuffling are unlikely produced by
simple exon skipping or 5' and 3' splice events. Cassette
exon events (and others such as alternating exon, and
intron retention) can often be complex exon events – i.e.
they often occur in association with extension/truncation
of either one or both the flanking exons. It has been doc-
umented in ASD web pages, that 27% instances of the
18815 inferred cassette exons occur in complex form (see
http://www.ebi.ac.uk/asd/altsplice/humrel3-dist-BMC Genomics 2008, 9:453 http://www.biomedcentral.com/1471-2164/9/453
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data.html). Of the reported 18815 cassette exon events,
13799 events occur only as simple cassette exons (SCE);
1418 events occur only as complex cassette exons (CCE);
and 3589 occur in both the SCE and CCE forms. Cassette
events involving successive multiple exons have also been
reported. Intron retention events are not seen as very rare.
Further, it is to be noted that an entire region of a domain
does not have to be necessarily removed; deletion of cru-
cial regions is enough to make the E-value of Pfam anno-
tation not acceptable. An interesting aspect to consider for
further studies relates to mechanistic connections
between alterations (insertion/deletion, truncation, alter-
nating, and reshuffle) of domains/fingerprints among
protein isoforms to the types (exon extension/truncation,
intron retention, cassette exon, alternating exon events)
and extents ('simple' or 'complex' as defined in the ASD
database) of splice events. We find interesting examples in
our data set where alterations of protein signatures are not
effected by variation in exons that code for such signatures
but rather by variations in upstream exons that shift the
reading frame; such an observation has been seen as prev-
alent in literature [42].
(iv) Concerns due to EST sequences in the ASD data set
The isoform splice patterns as inferred by the ASD pipe-
line are delineated from gene-transcript alignments; since
these transcripts (cDNA/EST/mRNA) are from different
sources and conditions, it leads to a concern that some of
the inferred full-length transcripts are chimeric isoforms.
However, this is not the case with the ASD pipeline for the
following reasons: Portions of a chimeric transcript are
generally from different chromosomes or from distant
regions of the same chromosome. Chimeric transcripts
usually pose problems when one assembles transcripts to
derive gene structures or full-length transcripts. The ASD
pipeline does not cluster transcripts to assemble full-
length transcripts; the pipeline maps transcripts onto
'known' genes from Ensembl [51] and delineate the
unique splice patterns. The methods adopted in the ASD
pipeline take care that chimeric EST's are not considered –
some of the relevant filter criteria (see [52] and the ASD
online documents at http://www.ebi.ac.uk/asd/documen
tation.html for more details) used are: (a) gene-transcript
alignments that involve transcript sequences matching
more than one gene are removed; (b) if a region of a tran-
script sequence matches more than one region of a gene,
then the transcript sequence is removed; (c) transcripts
that maps only to the flanking regions of a gene (consid-
ered is the Ensembl gene plus a region of 3000 bases
flanking the gene) are ignored; matches in gene-transcript
alignments of length less than a threshold are ignored; (d)
transcript-gene alignments that contain only a single
match on the gene are removed; and (e) gene-transcript
alignments that show gap between matches on the tran-
script sequences are removed.
(v) Concerns due to derivation of protein sequence in the ASD data 
set
EST libraries have a 5' bias (i.e. a fraction of cDNA/EST
sequences is truncated at the 5' end) and thus there can be
possibilities that some of the identified splice patterns in
computationally predicted data set are truncated at the 5'
end. Identification of coding sequence as the longest open
reading frame (ORF) from an ATG codon might provide a
truncated protein isoform sequence. However, for reasons
stated below, we believe that this concern has been
addressed to a large extent, if not completely, by the meth-
ods of the ASD pipeline. It is not that the longest ORF
from any ATG codon is considered; the context-sequence
of such an ATG should score higher than a threshold value
of the Kozak's ATG-context score [29]. The nucleotide
sequences around the translation-initiation ATG codon is
supposed to be distinctly different from those around the
non-initiation ATG codons. In the ASD pipeline, known
human mRNA sequences with experimentally determined
translation-initiation codon were collected and used to
define the threshold for the context score of initiation
ATG codons. Use of this step (along with others such as
match to a reference protein and requirement of a mini-
mal length) is expected to eliminate truncated peptide
sequences that start on any ATG on the splice pattern
sequence.
Use of Vega versus ASD databases for data on protein 
isoforms
In this work, we considered two distinct data types – one
comprising manually curated protein isoforms from Vega
and the other comprising protein isoforms as delineated
from EST resources by the ASD computational pipeline.
The estimates for orphan isoforms was seen much higher
with ASD data set – a possible reason for this is that the
ASD pipeline uses EST/mRNA transcript sequences, and as
briefed earlier, a majority of the EST libraries are con-
structed from diseased tissues; and hence some of the
observed protein isoforms are expressed only in diseased
state of the cell and they probably lack any function. How-
ever, in general, both the data resources lead to similar
results in terms of signatures that often undergo changes
among protein isoforms. This observation builds a case
for use of such computationally predicted databases that
are, in general, are larger in size than the manually curated
databases.
SpliVaP DATABASE
Contents of the database
The presented work led to developing a database that
holds data on protein isoforms with observed changes in
signatures and domains. The main tables of the database
are genes, protein isoforms, annotated domains & signa-
tures, and the changes among the isoforms. Presented in
the database are the genes and isoforms from Set D (seeBMC Genomics 2008, 9:453 http://www.biomedcentral.com/1471-2164/9/453
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the section on "Varying degrees of annotation of protein
isoforms for Pfam/PRINTS signatures"). The current
release 1 of the database holds (i) 4673 Vega genes with
19,827 protein isoform sequences that are annotated with
727 distinct fingerprint signatures (of which 637 could be
associated with at least one GO term) and 2057 distinct
Pfam domain signatures (of which 1242 could be associ-
ated with at least one GO term); and (ii) 2678 ASD genes
with 11,004 protein isoform sequences that are annotated
with 590 distinct fingerprint signatures (of which 528
could be associated with at least one GO term) and 1592
distinct Pfam domain signatures (of which 1012 could be
associated with at least one GO term).
Examination of the GO terms
Examining the GO terms (associated with the mapped fin-
gerprints and Pfam domains in our data set) reveal the fol-
lowing as the oft-affected molecular functions: binding
activity: (nucleic acid, protein, carbohydrate, lipid, cofac-
tor, chromatin, steroid, nucleotide, nucleoside, selenium,
oxygen); catalytic activity: (transferase, ligase, isomerase,
oxidoreductase, deaminase, integrase, helicase, hydrolase,
lyase, small protein activating enzyme); transcription reg-
ulator activity: (transcription activator, transcription
repressor, transcription initiation factor, transcription fac-
tor, transcription cofactor, RNA polII transcription factor,
two-component response regulator); structural molecule
activity: (structural constituent of nuclear pore, vitelline
membrane, ribosome, myelin sheath, extracellular
Illustration of a typical result page from the web access of SpliVaP database Figure 3
Illustration of a typical result page from the web access of SpliVaP database. Reported is the data on protein iso-
forms from PEPD gene. Reported changes in Pfam domains between two isoforms SP1 and SP4 (which are hyperlinked to 
splice patterns in ASD database) are an insertion/deletion and a truncation. Associations to a template structure entry in MSD, 
and to a related entry of genetic disorder in OMIM are shown and are hyperlinked.BMC Genomics 2008, 9:453 http://www.biomedcentral.com/1471-2164/9/453
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matrix); transporter activity: (drug, nucleocytoplasmic);
motor; and antioxidant activities.
Association with disease disorders
We made associations to disease disorders by using infor-
mation from OMIM database. The association seen in our
data sets between splice-mediated changes and disease
genes (Event Type: No. Of genes) are as follows: FOR
VEGA: Pfam domain truncation: 2281 disease genes;
Pfam domain insertion/deletion: 1406 disease genes;
Pfam domain swap: 28 disease genes; PRINTS Class_A
insertion/deletion: 159 disease genes; PRINTS class_B
insertion/deletion: 579 disease genes; PRINTS class_C
insertion/deletion: 65 disease genes; PRINTS class_D
insertion/deletion: 103 disease genes; and PRINTS swap:
4 disease genes. FOR ASD: Pfam domain truncation: 1319
disease genes; Pfam domain insertion/deletion: 806 dis-
ease genes; Pfam domain swap: 3 disease genes; PRINTS
Class_A insertion/deletion: 145 disease genes; PRINTS
class_B insertion/deletion: 516 disease genes; PRINTS
class_C insertion/deletion: 90 disease genes; PRINTS
class_D insertion/deletion: 141 disease genes; and
PRINTS swap: 1 disease genes.
Association with structural templates
Search for associations between protein isoform
sequences in our data set and data entries in Macromo-
lecular Structure Database resulted in a set of 836 Vega
genes (538 ASD genes). In each such gene, at least one
protein isoform sequence can be associated with an MSD
entry. In 699 of the 836 Vega genes (247 of the 538 ASD
genes), more than one isoform sequence could be associ-
ated with structural data; except for few cases, the template
entry from MSD was same for the multiple isoform
sequences from a gene. Examination of these data indi-
cated that such isoform sequences (with associations to
MSD entries) are often results of protein shortenings
(truncations) at either or both the N- and C-terminal
ends. The data of such associations and indications of tar-
get structure data are useful to those who want to do
homology modelling for studying structural effects of
alternative splicing.
The data can be accessed via a web query interface availa-
ble from our web site at http://www.bioinformat
ica.crs4.org/tools/dbs/splivap/. The interface allows the
users to query the database through (i) gene names, GO
terms, and keywords (on diseases, protein signatures &
protein descriptions); (ii) associations with MSD entry
and OMIM entry identifiers; (iii) types of changes (splice-
mediated changes in PRINTS fingerprints and in Pfam
domains); and (iv) against specific classes of PRINTS and
Pfam definitions. Cross-references have been made to
UniProt [28] for detailed protein information, Ensembl
[51] for detailed genome annotation information, ASD
for underlying transcript patterns, MSD for structural data
& visualizations, and OMIM for information on genetic
disorders. The interface provides an option to restrict the
query to only the genes and isoforms (from curated data
set) that are common between SpliVaP and Vega data sets.
Figure 3 shows an exemplary result page. Reported is the
data on protein isoforms from PEPD gene. Changes
(insertion/deletion and truncation of Pfam domains) are
seen between two isoforms SP1 and SP4. The isoforms are
hyperlinked to ASD database to show the underlying
splice patterns. Association to a template structure entry in
MSD, and to a related entry of genetic disorder in OMIM
is shown and is hyperlinked.
Utility of the SpliVaP Database
Several databases have been published in recent years to
provide access to alternative splicing data. Some of the
notable ones are HOLLYWOOD [53], ASAP II [54], H-
DBAS [55], Ecgene [56], FAST-DB[57], ASTALAVISTA
[58], ATD/ASD [27,59], ASPicDB [60]. Most of these data-
bases (ASD, ASAP II, ECgene and H-DBAS) deal mainly
with the collection of transcript isoforms at the nucleotide
level that are then annotated with functional features such
as InterPro [61] patterns, tissue specificity and literature
data describing the specific isoforms. Further, databases
such as Ensembl and SwissProt report splice-mediated
protein variants and annotate the protein sequences for
structural and functional features. Though many of these
databases can be queried through features of gene and
splice variants to obtain the underlying splice patterns
and protein coding features, they generally do not allow
the users to query for splice variants through specific
changes in the composition of specific signatures (such as
Pfam domains and PRINTS fingerprints) – the ability to
access splice-mediated protein isoforms through changes
in protein signatures (such as domain truncation or inser-
tion/deletion) as well as the ability to obtain pre-proc-
essed information reporting changes in functional motifs
among protein isoforms is missing. The SpliVaP database
that we present to the community fills this gap. Thus,
SpliVaP is useful for researchers in splicing community, in
particular to those who are interested in studying the func-
tional effects on protein variants. In addition, it is useful
to researchers working in disease biology to access dis-
ease-associated genes that express, through alternative
and aberrant splicing, proteins with altered functions –
the database contains 3014 Vega genes that are associated
with 2808 unique OMIM entries (ASD: 2038 genes, 2496
distinct OMIM entries). The presented association of pro-
tein isoforms with entries in structural database provides
structure templates that the users can utilize for structural
studies on splice-mediated changes in protein sequences.
Association of protein isoform sequences with structuralBMC Genomics 2008, 9:453 http://www.biomedcentral.com/1471-2164/9/453
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data entries from MSD could be made in the case of 836
Vega genes and 538 ASD genes.
Conclusion
The work presented here considers protein variants that
are (i) extracted from manually curated database of Vega,
and (ii) derived by ASD computational pipeline from
transcript sequences (EST/mRNA/cDNA), and reports
splice-mediated changes in protein isoforms.
Protein molecular functions that are often affected by
alternative splicing in our data sets are: binding activity,
catalytic activity, transcription regulator activity, structural
molecule activity, transporter activity, motor, and antioxi-
dant activities; major processes that are affected are regu-
lation of transcription, signal transduction, and protein-
protein interaction. This observation gains support from
previous studies (that use computationally predicted pro-
tein isoforms [6,8,62] or that use protein isoforms from
curated databases [37,63]) – see [5,9] for excellent
reviews). A diverse range of changes are seen among pro-
tein isoforms, from removal of a complete domain/finger-
print to truncation of a domain or removal of a
component motif of a fingerprint. Signatures can be seen
alternated between two protein isoforms, though at a
lower frequency than other events. The presented data
suggests that alternative splicing can act (i) to make pro-
teins lose completely functionalities of specific regions or
gain new/additional functionalities (through events such
as insertion/deletion of fingerprints/domains), or (ii) to
act as a modulator of function (through events such as
truncations of domains & fingerprints, and swap between
those of same classifications), or (iii) to change the pro-
tein function (through events as swap between signatures
of different classifications.
The following are novel aspects: (i) Swapping of domains/
signatures seems to occur often between those of same
family (Structural/Functional) classifications. (ii) Pfam
domains can be seen in varying lengths among protein
isoforms, and fingerprints can be seen with varying
number of constituent motifs among protein isoforms;
since such a variation is seen in a large number of genes
and protein isoforms, it could be a general mechanism to
modulate the protein function among isoforms. The
observation of truncation events gain support from stud-
ies by others – e.g. Kriventseva et al [63] find that disrup-
tion of sequence forming a domain (similar to domain
truncations) is seen in considerable fraction (up to 28%)
of splice variants. (iii) We speculate that some of the
splice-mediated protein isoform products may lack any
"known" function and such proteins isoforms are proba-
bly expressed in disease states of tissues; a conservative
estimate using data from the manually curated Vega is that
one in 9 genes can lead to a protein isoform of no
"known" function; and one in 18 expressed protein iso-
forms can be such an orphan isoform; the corresponding
numbers as seen with computationally predicted ASD
data set are: one in 5 genes and one in 10 isoforms.
The resultant data of protein isoforms that are annotated
for splice-mediated changes is presented to the commu-
nity as SpliVaP database through web query interfaces.
Data on protein variants are cross-referenced to underly-
ing transcript patterns, genome context, genetic disorders,
and structural data. It is our intention to update the data-
base regularly and expand in functionalities. A particu-
larly important expansion in functionalities is to develop
an automated procedure for extracting structural informa-
tion of alternatively spliced peptide regions and to include
in the database.
Availability and requirements
Release 1 of the SpliVaP data, presented in this manu-
script, is available from http://www.bioinformat
ica.crs4.org/tools/dbs/splivap/. Enquiries on accessing the
data can be mailed to splivap@crs4.it.
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